Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-19T02:21:00.847Z Has data issue: false hasContentIssue false
  • English
  • Français

ASPIRIN ADMINISTRATION FOR PREVENTION OF ADVERSE PREGNANCY OUTCOMES

Published online by Cambridge University Press:  23 August 2012

EMMANUEL BUJOLD ,
STÉPHANIE ROBERGE ,
SUZANNE DEMERS  and
KYPROS H NICOLAIDES
EMMANUEL BUJOLD*
Affiliation:
Departments of Obstetrics and Gynecology and Social and Preventive Medicine, Faculty of Medecine, Université Laval, Quebec City, Qc, Canada.
STÉPHANIE ROBERGE
Affiliation:
Departments of Obstetrics and Gynecology and Social and Preventive Medicine, Faculty of Medecine, Université Laval, Quebec City, Qc, Canada.
SUZANNE DEMERS
Affiliation:
Departments of Obstetrics and Gynecology and Social and Preventive Medicine, Faculty of Medecine, Université Laval, Quebec City, Qc, Canada.
KYPROS H NICOLAIDES
Affiliation:
Harris Birthright Research Centre of Fetal Medicine, King's College Hospital, London, United Kingdom.
*
Emmanuel Bujold, MD, MSc, FRCSC, Associate Professor, Department of Obstetrics and Gynecology and Social and Preventive Medicine, Faculty of Medicine, Université Laval, 2705 boulevard Laurier, Québec City, QC, Canada, G1V 4G2. email: emmanuel.bujold@crchul.ulaval.ca
Get access Rights & Permissions [Opens in a new window]

Extract

The prophylactic use of low-dose aspirin for prevention of preeclampsia has been an important research question in obstetrics for the last three decades. In 1979, Crandon and Isherwood observed that nulliparous women who had taken aspirin regularly during pregnancy were less likely to have preeclampsia than women who did not. In 1985, Beaufils et al published the first randomized trial suggesting that 150 mg aspirin and 300 mg dipyridamole daily from 3 months’ gestation onwards decreased the risk of preeclampsia, fetal growth restriction and stillbirth in high-risk women. Subsequently, more than 50 trials have been carried out throughout the world and a meta-analysis of these studies reported that the administration of low-dose aspirin in high-risk pregnancies is associated with a decrease in the rate of preeclampsia by approximately 10%. Consequently, several national professional bodies recommend that high-risk pregnancies should be treated with aspirin (50–150 mg daily).

Type
Review Article
Information
Fetal and Maternal Medicine Review , Volume 23 , Issue 3-4 , November 2012 , pp. 187 - 200
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1Crandon, AJ, Isherwood, DM. Effect of aspirin on incidence of pre-eclampsia. Lancet. 1979; 1: 1356.Google Scholar
2Beaufils, M, Uzan, S, Donsimoni, R, Colau, JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1: 840–42.Google Scholar
3Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA. Antiplatelet agents for prevention of pre-eclampsia: A meta-analysis of individual patient data. Lancet 2007; 369: 1791–798.CrossRefGoogle ScholarPubMed
4Magee, LA, Helewa, M, Moutquin, JM, von Dadelszen, P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30: S1–48.Google Scholar
5National Collaborating Centre for Women's and Children's Health. Commissioned by the national institute for health and clinical excellence. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. Cg107. 2011.Google Scholar
6Lowe, SA, Brown, MA, Dekker, GA, Gatt, S, McLintock, CK, McMahon, LPet al.Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 2009; 49: 242–46.Google Scholar
7Ministry of health report. 1929. Memorandum on antenatal clinics: Their conduct and scope. His Majesty's Stationery Office. London. 1930.Google Scholar
8Nicolaides, KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183–96.Google Scholar
9Bujold, E, Roberge, S, Lacasse, Y, Bureau, M, Audibert, F, Marcoux, Set al.Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 2010; 116: 402–14.Google Scholar
10Bujold, E, Roberge, S, Tapp, S, Giguere, Y. Opinion & hypothesis could early aspirin prophylaxis prevent against preterm birth? J Matern Fetal Neonatal Med 2011; 24: 966–67.Google Scholar
11Mesdaghinia, E, Talari, H, Abedzadeh-Kalahroudi, M. Effect of aspirin for prevention of preeclampsia in women with abnormal ultrasonic findings in uterine artery. Feyz 2011; 15: 98–104. http://feyz.hbi.ir/index.php?slc_lang=en&sid=1Google Scholar
12Villa, P, Taipale, P, Räikkönen, K, Hämäläinen, E, Pesonen, A, Kajantie, Eet al. Predo trial- acetylsalicylic acid in preventing pre-eclampsia in high-risk women. Pregnancy Hypertension 2010: S1–41.Google Scholar
13Villa, PM, Kajantie, E, Räikkönen, K, Pesonen, A-K, Hämäläinen, E, Vainio, Met al. Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebocontrolled PREDO trial and a meta-analysis of randomised trials. BJOG in pressGoogle Scholar
14Bakhti, A, Vaiman, D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertension Research 2011; 34: 1116–120.Google Scholar
15August, P, Helseth, G, Edersheim, T, Hutson, J, Druzin, M. Sustained relase, low-dose aspirin ameliorates but does not prevent preeclampsia (pe) in a high risk population. Proceedings of 9th International Congress, International Society for the Study of Hypertension. 1994: 72.Google Scholar
16Azar, R, Turpin, D. Effect of antiplatelet therapy in women at high risk for pregnancy-induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy. 1990: 257.Google Scholar
17Benigni, A, Gregorini, G, Frusca, T, Chiabrando, C, Ballerini, S, Valcamonico, Aet al.Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321: 357–62.Google Scholar
18Ebrashy, A, Ibrahim, M, Marzook, A, Yousef, D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery doppler ultrasound at 14–16 weeks pregnancy: Randomized controlled clinical trial. Croat Med J 2005; 46: 826–31.Google Scholar
19Hermida, RC, Ayala, DE, Iglesias, M, Mojon, A, Silva, I, Ucieda, Ret al.Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension 1997; 30: 589–95.CrossRefGoogle ScholarPubMed
20Michael, C, Walters, B. Low-dose aspirin in the prevention of pre-eclampsia: Current evaluation. Maternal physiology and pathology. The current status of gynaecology and obstetrics serie. 1992; Maternal physiology and pathology. The current status of gynaecology and obstetrics series: 183–89.Google Scholar
21Tulppala, M, Marttunen, M, Soderstrom-Anttila, V, Foudila, T, Ailus, K, Palosuo, Tet al.Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: Effect on prostacyclin and thromboxane a2 production. Hum Reprod 1997; 12: 1567–572.Google Scholar
22Vainio, M, Kujansuu, E, Iso-Mustajarvi, M, Maenpaa, J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109: 161–67.Google ScholarPubMed
23Roberge, S, Villa, P, Nicolaides, K, Giguere, Y, Vainio, M, Bakthi, Aet al.Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis. Fetal Diagn Ther 2012; 31: 141–46.Google Scholar
24Roberge, S, Giguere, Y, Villa, P, Nicolaides, K, Vainio, M, Forest, JCet al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–56.Google Scholar
25Clasp: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Clasp (collaborative low-dose aspirin study in pregnancy) collaborative group. Lancet 1994; 343: 619–29.Google Scholar
26Moldenhauer, JS, Stanek, J, Warshak, C, Khoury, J, Sibai, B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189: 1173–177.CrossRefGoogle ScholarPubMed
27Sebire, NJ, Goldin, RD, Regan, L. Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol. 2005; 25: 117–18.CrossRefGoogle ScholarPubMed
28Vatten, LJ, Skjaerven, R. Is pre-eclampsia more than one disease? BJOG 2004; 111: 298–302.Google Scholar
29Xiong, X, Demianczuk, NN, Saunders, LD, Wang, FL, Fraser, WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002; 155: 203–209.Google Scholar
30Odegard, RA, Vatten, LJ, Nilsen, ST, Salvesen, KA, Austgulen, R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950–55.Google ScholarPubMed
31Xiao, R, Sorensen, TK, Williams, MA, Luthy, DA. Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13: 157–62.Google Scholar
32Yu, CK, Khouri, O, Onwudiwe, N, Spiliopoulos, Y, Nicolaides, KH. Prediction of pre-eclampsia by uterine artery doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–13.Google Scholar
33Groeneveld, E, Broeze, KA, Lambers, MJ, Haapsamo, M, Dirckx, K, Schoot, BCet al.Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA). Hum Reprod Update 2011; 17: 501–509.CrossRefGoogle ScholarPubMed
34Lambers, MJ, Groeneveld, E, Hoozemans, DA, Schats, R, Homburg, R, Lambalk, CBet al.Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod 2009; 24: 2447–450.Google Scholar
35Haapsamo, M, Martikainen, H, Tinkanen, H, Heinonen, S, Nuojua-Huttunen, S, Rasanen, J. Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: A randomized, placebo-controlled, double-blind study. Hum Reprod 2010; 25: 2972–977.Google Scholar
36Kaandorp, SP, Goddijn, M, van der Post, JA, Hutten, BA, Verhoeve, HR, Hamulyak, Ket al.Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586–596.Google Scholar
37Siristatidis, CS, Dodd, SR, Drakeley, AJ. Aspirin is not recommended for women undergoing IVF. Hum Reprod Update 2012; 18: 233.Google Scholar
38Masotti, G, Galanti, G, Poggesi, L, Abbate, R, Neri Serneri, GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979; 2: 1213–217.Google Scholar
39Steegers, EA, von Dadelszen, P, Duvekot, JJ, Pijnenborg, R. Pre-eclampsia. Lancet 2010; 376: 631–44.Google Scholar
40Brosens, IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4: 573–93.Google Scholar
41Pijnenborg, R, Dixon, G, Robertson, WB, Brosens, I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980; 1: 3–19CrossRefGoogle ScholarPubMed
42Haapsamo, M, Martikainen, H, Rasanen, J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: A randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol 2008; 32: 687–93.Google Scholar
43Kim, YM, Bujold, E, Chaiworapongsa, T, Gomez, R, Yoon, BH, Thaler, HTet al.Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003; 189: 1063–1069.Google Scholar
44Kim, YM, Chaiworapongsa, T, Gomez, R, Bujold, E, Yoon, BH, Rotmensch, Set al.Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002; 187: 1137–142.Google Scholar
45Lewis, RB, Schulman, JD. Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet 1973; 2: 1159–161.Google Scholar
46Slone, D, Siskind, V, Heinonen, OP, Monson, RR, Kaufman, DW, Shapiro, S. Aspirin and congenital malformations. Lancet 1976; 1: 1373–375.Google Scholar
47Werler, MM, Mitchell, AA, Shapiro, S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 1639–1642.Google Scholar
48Norgard, B, Puho, E, Czeizel, AE, Skriver, MV, Sorensen, HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: A population-based case-control study. Am J Obstet Gynecol 2005; 192: 922–23.Google Scholar
49Klebanoff, MA, Berendes, HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology 1988; 37: 249–255.Google Scholar
50Keim, SA, Klebanoff, MA. Aspirin use and miscarriage risk. Epidemiology 2006; 17: 435–39.Google Scholar
51Hernandez, RK, Werler, MM, Romitti, P, Sun, L, Anderka, M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol 2011; 206: 228.Google Scholar
52Levy, G, Procknal, JA, Garrettson, LK. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. Clin Pharmacol Ther 1975; 18: 210–14.Google Scholar
53Levy, G, Garrettson, LK. Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 1974; 53: 201–10.Google Scholar
54Sibai, BM, Mirro, R, Chesney, CM, Leffler, C. Low-dose aspirin in pregnancy. Obstet Gynecol 1989; 74: 551–57.Google Scholar
55Schiessl, B, Schneider, KT, Zimmermann, A, Kainer, F, Friese, K, Oberhoffer, R. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication? Z Geburtshilfe Neonatol 2005; 209: 65–68.Google Scholar
56Wyatt-Ashmead, J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol 2011; 14: 469–74.Google Scholar
57Di Sessa, TG, Moretti, ML, Khoury, A, Pulliam, DA, Arheart, KL, Sibai, BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994; 171: 892–900.Google Scholar
58Leonhardt, A, Bernert, S, Watzer, B, Schmitz-Ziegler, G, Seyberth, HW. Low-dose aspirin in pregnancy: Maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics 2003; 111: e77–81.Google Scholar
59Bleyer, WA, Breckenridge, RT. Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. JAMA. 1970; 213: 2049–2053.Google Scholar
60Corby, DG, Schulman, I. The effects of antenatal drug administration on aggregation of platelets of newborn infants. J Pediatr 1971; 79: 307–13.Google Scholar
61Duley, L, Henderson-Smart, DJ, Meher, S, King, JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007: CD004659.Google Scholar
62Rotchell, YE, Cruickshank, JK, Gay, MP, Griffiths, J, Stewart, A, Farrell, Bet al.Barbados low dose aspirin study in pregnancy (blasp): A randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105: 286–92.Google Scholar
63Sibai, BM, Caritis, SN, Thom, E, Klebanoff, M, McNellis, D, Rocco, Let al.Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The national institute of child health and human development network of maternal-fetal medicine units. N Engl J Med. 1993; 329: 1213–218.Google Scholar
64Caritis, S, Sibai, B, Hauth, J, Lindheimer, MD, Klebanoff, M, Thom, Eet al.Low-dose aspirin to prevent preeclampsia in women at high risk. National institute of child health and human development network of maternal-fetal medicine units. N Engl J Med 1998; 338: 701–705.Google Scholar
65Subtil, D, Goeusse, P, Puech, F, Lequien, P, Biausque, S, Breart, Get al.Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The essai regional aspirine mere-enfant study (part 1). BJOG 2003; 110: 475–84.Google Scholar
66Hauth, JC, Goldenberg, RL, Parker, CR Jr., Cutter, GR, Cliver, SP. Low-dose aspirin: Lack of association with an increase in abruptio placentae or perinatal mortality. Obstet Gynecol 1995; 85: 1055–1058Google Scholar
67Sibai, BM, Caritis, SN, Thom, E, Shaw, K, McNellis, D. Low-dose aspirin in nulliparous women: Safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National institute of child health and human developmental maternal-fetal medicine network. Am J Obstet Gynecol 1995; 172: 1553–557.Google Scholar
68Caron, N, Rivard, GE, Michon, N, Morin, F, Pilon, D, Moutquin, JM, Rey, E. Low-dose asa response using the pfa-100 in women with high-risk pregnancy. J Obstet Gynaecol 2009; 31: 1022–1027.Google Scholar
69Rey, E, Rivard, GE. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol Reprod Biol 2011; 157: 38–42.Google Scholar
70Vainio, M, Maenpaa, J, Riutta, A, Ylitalo, P, Ala-Fossi, SL, Tuimala, R. In the dose range of 0.5–2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies. Acta Obstet Gynecol Scand 1999; 78: 82–88Google Scholar
71Dumont, A, Flahault, A, Beaufils, M, Verdy, E, Uzan, S. Effect of aspirin in pregnant women is dependent on increase in bleeding time. Am J Obstet Gynecol 1999; 180: 135–40.CrossRefGoogle ScholarPubMed
72Wojtowicz, A, Undas, A, Huras, H, Musial, J, Rytlewski, K, Reron, Aet al.Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett 2011; 32: 334–39.Google Scholar
73Homoncik, M, Jilma, B, Hergovich, N, Stohlawetz, P, Panzer, S, Speiser, W. Monitoring of aspirin (asa) pharmacodynamics with the platelet function analyzer pfa-100. Thromb Haemost 2000; 83: 316–21.Google Scholar
74Spencer, K, Yu, CK, Cowans, NJ, Otigbah, C, Nicolaides, KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free BETA-HCG and with second-trimester uterine artery doppler. Prenat Diagn 2005; 25: 949–53.Google Scholar
75Poon, LC, Kametas, NA, Valencia, C, Chelemen, T, Nicolaides, KH. Hypertensive disorders in pregnancy: Screening by systolic diastolic and mean arterial` pressure at 11–13 weeks. Hypertens Pregnancy 2011; 30: 93–107.CrossRefGoogle ScholarPubMed
76Akolekar, R, Etchegaray, A, Zhou, Y, Maiz, N, Nicolaides, KH. Maternal serum activin a at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009; 25: 320–27.Google Scholar
77Akolekar, R, Minekawa, R, Veduta, A, Romero, XC, Nicolaides, KH. Maternal plasma inhibin a at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009; 29: 753–60.Google Scholar
78Akolekar, R, Syngelaki, A, Beta, J, Kocylowski, R, Nicolaides, KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29: 1103–108.Google Scholar
79Karagiannis, G, Akolekar, R, Sarquis, R, Wright, D, Nicolaides, KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 2011; 29: 148–54.Google Scholar
80Poon, LC, Kametas, NA, Chelemen, T, Leal, A, Nicolaides, KH. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens 2010; 24: 104–10.Google Scholar
81Poon, LC, Kametas, NA, Maiz, N, Akolekar, R, Nicolaides, KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812–18.Google Scholar
82Poon, LC, Kametas, NA, Pandeva, I, Valencia, C, Nicolaides, KH. Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of preeclampsia. Hypertension 2008; 51: 1027–1033Google Scholar
83Syngelaki, A, Bredaki, FE, Vaikousi, E, Maiz, N, Nicolaides, KH. Body mass index at 11–13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther 2011; 30: 250–65.Google Scholar
84Smith, GC, Yu, CK, Papageorghiou, AT, Cacho, AM, Nicolaides, KH. Maternal uterine artery doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol. 2007; 109: 144–51.Google Scholar
85Akolekar, R, Syngelaki, A, Sarquis, R, Zvanca, M, Nicolaides, KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 1: 66–74Google Scholar
86Giguere, Y, Charland, M, Bujold, E, Bernard, N, Grenier, S, Rousseau, Fet al.Combining biochemical and ultrasonographic markers in predicting preeclampsia: A systematic review. Clin Chem 2010; 56: 361–75.Google Scholar
87Bujold, E, Morency, AM, Roberge, S, Lacasse, Y, Forest, JC, Giguere, Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery doppler: A systematic review and meta-analysis. J Obstet Gynaecol Can 2009; 31: 818–26.Google Scholar